Reassessment of clinical variables in cardiac resynchronization defibrillator patients at the time of first replacement: Death after replacement of CRT (DARC) score

J Cardiovasc Electrophysiol. 2021 Jun;32(6):1687-1694. doi: 10.1111/jce.15031. Epub 2021 Apr 30.

Abstract

Introduction: Cardiac resynchronization defibrillator (CRT-D) as primary prevention is known to reduce mortality. At the time of replacement, higher age and comorbidities may attenuate the benefit of implantable cardioverter-defibrillator (ICD) therapy. The purpose of this study was to evaluate the progression of comorbidities after implantation and their association with mortality following CRT-D generator replacement. In addition, a risk score was developed to identify patients at high risk for mortality after replacement.

Methods and results: We identified patients implanted with a primary prevention CRT-D (n = 648) who subsequently underwent elective generator replacement (n = 218) from two prospective ICD registries. The cohort consisted of 218 patients (median age: 70 years, male gender: 73%, mean left ventricular ejection fraction [LVEF]: 36 ± 11% at replacement). Median follow-up after the replacement was 4.2 years during which 64 patients (29%) died and 11 patients (5%) received appropriate ICD shocks. An increase in comorbidities was observed in 77 patients (35%). The 5-year mortality rate was 41% in patients with ≥2 comorbidities at the time of replacement. A risk score incorporating age, gender, LVEF, atrial fibrillation, anemia, chronic kidney disease, and history of appropriate ICD shocks at time of replacement accurately predicted 5-year mortality (C-statistic 0.829). Patients with a risk score of greater than 2.5 had excess mortality at 5-year postreplacement compared with patients with a risk score less than 1.5 (57% vs. 6%; p < .001).

Conclusion: A simple risk score accurately predicts 5-year mortality after replacement in CRT-D patients, as patients with a risk score of greater than 2.5 are at high risk of dying despite ICD protection.

Keywords: cardiac resynchronization therapy; comorbidity; implantable cardioverter-defibrillator; mortality; primary prevention.

MeSH terms

  • Aged
  • Atrial Fibrillation* / therapy
  • Cardiac Resynchronization Therapy* / adverse effects
  • Defibrillators, Implantable*
  • Heart Failure* / diagnosis
  • Heart Failure* / therapy
  • Humans
  • Male
  • Prospective Studies
  • Risk Factors
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Function, Left